Follicular Lymphoma

Common Name(s)

Follicular Lymphoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Follicular Lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Follicular Lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Follicular Lymphoma" returned 739 free, full-text research articles on human participants. First 3 results:

18F-Fluorodeoxyglucose positron emission tomography computed tomography detection threshold in follicular lymphoma: A case report.
 

Author(s): Sarah Péricart, Guillaume Martin-Blondel, Camille Franchet, Anne Hitzel, Pierre Brousset

Journal: Medicine (Baltimore). 2017 Nov;96(47):e8705.

 

Follicular Lymphoma in situ is generally identified as reactive follicular hyperplasia in which some of the hyperplastic germinal centers are colonized by few lymphoma cells. These cells can be detected through their strong 18F-Fluorodeoxyglucose avidity.

Last Updated: 31 Dec 1969

Go To URL
Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.
 

Author(s): Ana Jiménez-Ubieto, Carlos Grande, Dolores Caballero, Lucrecia Yáñez, Silvana Novelli, Miguel T Hernández, María Manzanares, Reyes Arranz, José Javier Ferreiro, Sabela Bobillo, Santiago Mercadal, Andrea Galego, Javier López Jiménez, José María Moraleda, Carlos Vallejo, Carmen Albo, Elena Pérez, Carmen Marrero, Laura Magnano, Luis Palomera, Isidro Jarque, Erika Coria, Antonia Rodriguez, Alejandro Martín, Armando López-Guillermo, Antonio Salar, Juan José Lahuerta,

Journal: Cancer Med. 2017 Dec;6(12):2766-2774.

 

Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier end points, proposed in the ...

Last Updated: 31 Dec 1969

Go To URL
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
 

Author(s): Robert Marcus, Andrew Davies, Kiyoshi Ando, Wolfram Klapper, Stephen Opat, Carolyn Owen, Elizabeth Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann

Journal: N. Engl. J. Med.. 2017 10;377(14):1331-1344.

 

Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Follicular Lymphoma" returned 81 free, full-text review articles on human participants. First 3 results:

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
 

Author(s): Koorosh Korfi, Sara Ali, James A Heward, Jude Fitzgibbon

Journal: Epigenetics. 2017 05;12(5):370-377.

 

While follicular lymphoma (FL) is exquisitely responsive to immuno-chemotherapy, many patients follow a relapsing remitting clinical course driven in part by a common precursor cell (CPC) population. Advances in next generation sequencing have provided valuable insights into the genetic ...

Last Updated: 31 Dec 1969

Go To URL
Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.
 

Author(s): Takumi Sugimoto, Takashi Watanabe

Journal: J Clin Exp Hematop. 2016 ;56(1):1-19.

 

The microenvironment of follicular lymphoma (FL) is composed of tumor-infiltrating CD8(+) T cells, follicular regulatory T cells, lymphoma-associated macrophages and mast cells, follicular helper T cells, follicular dendritic cells, and follicular reticular cells, all of which have ...

Last Updated: 31 Dec 1969

Go To URL
Follicular lymphoma: evolving therapeutic strategies.
 

Author(s): Brad S Kahl, David T Yang

Journal: Blood. 2016 04;127(17):2055-63.

 

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. After decades of stagnation, the natural history of FL appears to have been favorably impacted by the introduction of rituximab. Randomized clinical trials have demonstrated that the ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma
 

Status: Not yet recruiting

Condition Summary: Follicular Lymphoma

 

Last Updated: 12 Mar 2018

Go to URL
TGR1202 in Relapsed and Refractory Follicular Lymphoma
 

Status: Recruiting

Condition Summary: Follicular Lymphoma

 

Last Updated: 8 Mar 2018

Go to URL